Moleculin Biotech, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
5300 MEMORIAL DRIVE, HOUSTON, TX, 77007
Mailing Address
5300 MEMORIAL DRIVE, HOUSTON, TX, 77007
Phone
713-300-5160
Fiscal Year End
1231
EIN
474671997
Financial Overview
FY2025 FY
-
Revenue
$22.13M
Total Assets
$30.93M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 18, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 18, 2026
- Advancing innovative small molecule drugs for difficult-to-treat cancers and viral diseases.
- Lead drug candidates are progressing through various phases of clinical trials.
Material Events
8-K
Financial Distress
January 7, 2026
High Impact
- Moleculin Biotech successfully regained compliance with Nasdaq's minimum stockholders' equity requirement.
- The company has avoided delisting from the Nasdaq stock exchange.
8-K
Financial Distress
December 22, 2025
High Impact
- Moleculin Biotech raised $7.9 million through warrant exercises and direct stock sales.
- These financial moves were made to address a potential Nasdaq delisting due to not meeting financial requirements.
8-K
Other
December 16, 2025
High Impact
- Moleculin Biotech, Inc. successfully regained compliance with Nasdaq's minimum bid price requirement.
- The company's stock closed at or above $1.00 for 10 consecutive business days, from December 1st to December 12th, 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.